Factor 10a Brand Name– ANDEXXA
What is Factor 10a
Factor 10a is a parenteral, recombinant modified human Factor 10a protein indicated for reversal of apixaban or rivaroxaban anticoagulation in patients with life-threatening or uncontrolled bleeding.
In clinical trials, anti-factor Xa activity decreased rapidly and substantially in response to the Factor 10a bolus compared to baseline; decreased anti-factor Xa activity was sustained through the end of the Factor 10a continuous infusion. An improvement in hemostasis has not been established.
Factor 10a has been associated with serious and life-threatening adverse events including arterial and venous thromboembolism, myocardial infarction, ischemic stroke, cardiac arrest, and sudden death.
To reduce thromboembolic risk, resume anticoagulant therapy as soon as medically appropriate after Factor 10a treatment.
Factor 10a has not been shown to be effective for and is not indicated for the treatment of bleeding related to any Factor 10a inhibitors other than apixaban and rivaroxaban
Indications
- apixaban reversal
- rivaroxaban reversal
For rivaroxaban reversal and apixaban reversal in patients with life-threatening or uncontrolled bleeding
Side Effects
- antibody formation
- cardiac arrest
- cough
- dysgeusia
- dyspnea
- flushing
- heart failure
- infection
- infusion-related reactions
- myocardial infarction
- pulmonary embolism
- stroke
- thromboembolism
- thrombosis
- ventricular tachycardia
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- disseminated intravascular coagulation (DIC)
- pregnancy
- thromboembolism
Interactions
There are no drug interactions associated with Factor 10a products.
